|1.||Hewitt, L Arthur: 5 articles (04/2015 - 01/2014)|
|2.||Kaufmann, Horacio: 4 articles (01/2015 - 03/2008)|
|3.||Biaggioni, Italo: 3 articles (01/2015 - 07/2014)|
|4.||Mathias, Christopher J: 3 articles (01/2015 - 03/2008)|
|5.||Ikemoto, Keiko: 3 articles (05/2004 - 08/2002)|
|6.||Isaacson, Stuart: 2 articles (04/2015 - 01/2014)|
|7.||Hauser, Robert A: 2 articles (04/2015 - 01/2014)|
|8.||Freeman, Roy: 2 articles (01/2015 - 07/2014)|
|9.||Low, Phillip: 2 articles (01/2015 - 07/2014)|
|10.||Wang, Jingzhou: 1 article (10/2015)|
|1.||Orthostatic Hypotension (Postural Hypotension)
01/01/2015 - "Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes of this trial. "
02/01/2015 - "Oral droxidopa was effective in the shorter-term treatment of patients with symptomatic neurogenic orthostatic hypotension, with improvements seen in symptoms, the impact of symptoms on daily activities and standing systolic blood pressure. "
09/15/2015 - "In addition, two randomized, placebo-controlled, double-blind trials have studied the efficacy of droxidopa in the symptomatic treatment of neurogenic orthostatic hypotension, including patients with MSA, with positive results in one trial. "
03/01/1999 - "The enhanced responses of these vasoactive mediators by L-threo-DOPS during head-up tilt may contribute to the improvement in orthostatic hypotension in patients with MSA."
01/01/2015 - "Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa."
|2.||Parkinson Disease (Parkinson's Disease)
01/01/1997 - "Furthermore, L-threo-DOPS, nor-adrenergic precursor drug, is sometimes effective for the advanced stage of Parkinson's disease. "
01/01/2008 - "L-Threo-DOPS has been reported to have a symptomatic beneficial effect in patients with pure freezing syndrome, but small-scale, controlled trials in Parkinson's disease could not support those early observations. "
02/01/1998 - "Effects of L-threo-Dops (Dops) administration on orthostatic hypotention were evaluated with changes in blood pressure by postural change (lying to standing position) and subjective symptoms in 15 patients of Parkinson's disease having symptoms of orthostatic hypotention. "
01/01/1997 - "L-threo-DOPS was a poor precursor for NA and also failed to influence extracellular DA in striatum, questioning its use in the treatment of freezing gait in late stages of Parkinson's disease."
01/01/1989 - "Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease."
07/22/2014 - "Improvement in OHQ symptom subscore favored droxidopa by 0.73 units (p = 0.010), with maximum change in "dizziness/lightheadedness." Improvement in symptom-impact subscore favored droxidopa by 1.06 units (p = 0.003), with maximum change for "standing a long time." Mean standing systolic blood pressure (BP) increased by 11.2 vs 3.9 mm Hg (p < 0.001), and mean supine systolic BP by 7.6 vs 0.8 mm Hg (p < 0.001). "
01/01/2014 - "At Week 1, mean dizziness/lightheadedness score change favored droxidopa by 1.5 units (p = 0.24), with subsequent numerical differences favoring droxidopa throughout the observation period, and at Week 1, mean standing systolic blood-pressure change favored droxidopa by 12.5 mmHg (p = 0.04). "
04/15/2015 - "For the initial 51 subjects (study nOH306A, previously reported), the primary efficacy measure, Orthostatic Hypotension Questionnaire (OHQ) composite score, did not demonstrate significant change versus placebo at maintenance week 8. For the subsequent 171 subjects (study nOH306B, reported here), the primary efficacy measure was change versus placebo on item 1 ("dizziness, lightheadedness, feeling faint, or feeling like you might black out") of the Orthostatic Hypotension Symptom Assessment (OHSA) subsection of the OHQ at maintenance week 1. At week 1, mean (standard deviation) improvement on OHSA item 1 was 2.3 (2.95) for droxidopa versus 1.3 (3.16) for placebo (P = 0.018). "
01/01/2015 - "Mean worsening of Orthostatic Hypotension Questionnaire dizziness/lightheadedness score from randomization to end of study (the primary outcome; N=101) was 1.9±3.2 with placebo and 1.3±2.8 units with droxidopa (P=0.509). "
04/15/2015 - "The most common AEs on droxidopa (vs. placebo) were headache (13.5% vs. 7.3%) and dizziness (10.1% vs. 4.9%). "
10/01/2015 - "Individual motor symptoms such as stiffness, resting tremor, and alternate hand motion were also significantly improved with droxidopa on days 14 and 57 of treatment (P < 0.01 vs placebo), showing that droxidopa is effective in improving rigidity, tremor and alternate motion of hand. "
10/01/2015 - "Droxidopa was effective as symptomatic adjunct therapy, improved significantly motor function and activities of daily living, benefited patients with signs of tremor and Stiffness."
11/01/1994 - "That is, Tanaka (Kobe Univ.) showed that L-threo-DOPS is the real l-NE precursor among four DOPS-enantiomers, and that it has several pharmacological activities such as a slow-onset and long-lasting pressor effect, an inhibitory effect on harmaline-induced tremor and so on. "
04/01/1976 - "3) The development and duration of tremor induced by harmaline (10 mg/kg i.p.) were inhibited significantly in a dose dependent manner by L-threo-DOPS (50, 70, 100, 150 and 200 mg/kg i.p.), but neither by D-threo-DOPS (200 mg/kg i.p.) nor DL-erythro-DOPS (200 mg/kg i.p.). "
10/01/2015 - "The primary objective was to evaluate the efficacy and safety of droxidopa as add-on therapy in improving stiffness, tremors and other motor functions and activities of daily living for moderate-to-severe Parkinson's disease (PD). "
05/01/1988 - "The case is reported of a 57-year-old woman with familial amyloidotic polyneuropathy and concomitant orthostatic hypotension for which L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) was clinically effective. "
07/01/1991 - "The effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), an unnatural norepinephrine precursor, on alpha 2-adrenergic receptors in platelet membranes were investigated in a patient with familial amyloidotic polyneuropathy, two patients with multiple system atrophy, and two patients with Parkinson's disease. "
|3.||Levodopa (L Dopa)
|5.||Aromatic Amino Acids (Aromatic Amino Acid)
|7.||Atrial Natriuretic Factor (ANF)
|8.||Serotonin (5 Hydroxytryptamine)
|1.||Drug Therapy (Chemotherapy)
|2.||Activities of Daily Living (ADL)